- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Fuji Pharma to Sell Alvotech's Biosimilar Ustekinumab in Japan
Fuji Pharma will market Alvotech’s biosimilar ustekinumab in Japan, the companies announced this month.
Fuji Pharma will market Alvotech’s biosimilar ustekinumab in Japan, the companies announced this month.
Alvotech will receive an upfront payment of $4.6 million as a part of the transaction, with rights to receive total milestone payments up to $20 million. Alvotech will assume responsibility for full development and commercial supply out of its new manufacturing facility in Reykjavik, Iceland.
The agreement comes a few months after Fuji Pharma recently agreed to invest $50 million in Alvotech.
Ustekinumab references Janssen pharmaceuticals’ Stelara, which is approved to treat plaque psoriasis, psoriatic arthritis and Crohn disease. Johnson & Johnson, Janssen’s parent company, reported that, last year, Stelara generated approximately $5.2 billion worldwide in net revenues.
Alvotech‘s initial pipeline consists of 6 biosimilar monoclonal antibodies and fusion proteins aimed at treating severe immune, inflammatory conditions.
In Japan, there are 8 biosimilars currently approved, including 1 insulin glargine. Of the remaining products, 3 are biosimilar filgrastim products (of which 1 is developed by Fuji Pharma), 1 is a biosimilar infliximab, 1 is a biosimilar somatropin, and 1 is a biosimilar epoetin alfa. In addition, late last year Daiichi Sankyo announced that it launched its biosimilar trastuzumab, trastuzumab BS, referencing Herceptin.
Last month, Alvotech started enrollment for its phase 3 clinical study of AVT02, a proposed adalimumab biosimilar referencing Humira.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
